Form 8-K - Current report:
SEC Accession No. 0001628280-24-043761
Filing Date
2024-10-25
Accepted
2024-10-25 08:05:43
Documents
22
Period of Report
2024-10-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20241025.htm   iXBRL 8-K 29681
2 EX-99.1 aquestivetherapeutics-ac.htm EX-99.1 14037
3 EX-99.2 acaai_abstracts-final.htm EX-99.2 3025
4 EX-99.3 acaai2024poster-final.htm EX-99.3 6761
8 acaai2024poster-final001.jpg GRAPHIC 194806
9 acaai_abstracts-final001.jpg GRAPHIC 191376
10 aquestivetherapeutics-ac001.jpg GRAPHIC 265294
11 aquestivetherapeutics-ac002.jpg GRAPHIC 272829
12 aquestivetherapeutics-ac003.jpg GRAPHIC 333678
13 aquestivetherapeutics-ac004.jpg GRAPHIC 43856
  Complete submission text file 0001628280-24-043761.txt   1983018

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20241025.xsd EX-101.SCH 1776
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20241025_lab.xml EX-101.LAB 21629
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20241025_pre.xml EX-101.PRE 12504
24 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20241025_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 241394334
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)